WuXi Biologics, a leading contract research, development and manufacturing organization (CRDMO), provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients through our comprehensive and high-quality drug development model.
Using our industry-leading team of cell culture, purification and analytical experts, the Protein Generation Services group generates high-quality, research-grade proteins and antibodies to meet our clients’ schedules and requirements. No project is too large or small. Our team of experts can support preparation and purification of the most complex proteins or provide one to hundreds of monoclonal, bispecific and multispecific antibodies and other recombinant proteins for our clients’ diverse needs including early-stage discovery research, lead candidate screening, immunizations, in vivo studies, biochemical assays, crystal structure analysis, and other research purposes.
The WuXianTM Platform provides limitless custom protein generation services due to our large, dedicated protein production team and extensive capacities.
- Program Features
- Unique AI codon optimization process and high-expression platforms
- High-throughput automated expression, purification and analytics system
- Extensive bispecific antibody expression and purification toolbox to help ensure successful delivery of these complex molecules
- One-stop customized service according to customers’ needs
- Unlimited Capacity
- 5,000+ proteins delivered each year
- 1,300+ bispecific antibodies produced
- 3,500+ antigens manufactured
- Fast initiation and execution of projects